Dose Escalation Study of Pazopanib Plus TH-302
NCT01485042
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
50
Enrollment
OTHER
Sponsor class
Conditions
Solid Tumors
Interventions
DRUG:
Pazopanib and TH-302
Sponsor
Herbert Hurwitz, MD
Collaborators
[object Object]
[object Object]
[object Object]